Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Go Vida Plena vs JRNYS

Go Vida Plena
Graded #151

Higher grade

vs+5.700000000000003
JRNYS
Graded #267

Lower grade

The verdict

Go Vida Plena takes it — 68.2/100 to 62.5/100.

Go Vida Plena grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Go Vida Plena is a Spanish-first, Latino-focused medical weight-loss program offering GLP-1 therapy from $199/month, based in Utah.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGo Vida Plena +9
54
45
Dose & formulationGo Vida Plena +17
75
58
Clinical oversightJRNYS +1
83
84
Labs & monitoringJRNYS +8
63
71
FulfillmentGo Vida Plena +12
77
65
Contract termsEven
55
55
Go Vida Plena · left barJRNYS · right bar

The numbers

MetricGo Vida PlenaJRNYS
WeighScore68.2/10062.5/100
GradeCC
Scorecard rank#151#267
Semaglutide$199/mo (starting dose, compounded)Not disclosed
Tirzepatide$269/mo (starting dose, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Go Vida Plena

Graded #151 · C

Strengths

  • Spanish-first, fully bilingual GLP-1 program tailored to Latino food and lifestyle - a genuinely underserved niche
  • Compounded semaglutide, tirzepatide, and oral semaglutide from $199/mo, with installment pay (Klarna, Afterpay, Affirm)
  • Free initial consultation; medications shipped discreetly to your door after a medical evaluation
  • Includes 24/7 support, 4 virtual visits a year, and ongoing nutrition coaching
  • Physician-supervised program (Utah medical backing) with continuous follow-up

Where it loses points

  • Utah-based, and the full list of states served is not published
  • Only a '$199/mo starting' price is shown upfront; tirzepatide and oral-semaglutide pricing isn't published
  • The compounding pharmacy is not named (a 'provider pharmacies' page exists but lists no name)
  • Compounded GLP-1 medications are not FDA-approved - not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • No LegitScript certification displayed
JRNYS

Graded #267 · C

Strengths

  • Branded, FDA-approved GLP-1s — Wegovy, Ozempic, Zepbound, Mounjaro and Saxenda — rather than compounded copies
  • The membership band is published before intake and is banded openly by level of coach support
  • Medical visits, daily monitoring and 1-on-1 coaching are included in the membership at every tier
  • Led by CMO Dr. Henry Legere (UC Berkeley, Columbia medicine, Harvard fellowship)
  • Members with commercial insurance may pay around $25 a month for the medication after any deductible

Where it loses points

  • The membership is overhead, not a medication price: it covers visits, monitoring and coaching, and the FAQ says medication pricing is confirmed only after a provider consultation
  • No self-pay drug price is published anywhere, so the cost of a month cannot be worked out before signing up
  • The best case depends on commercial insurance coverage; without it the medication cost is unknown
  • No compounded option is disclosed — the programme is brand-focused, and brand list prices are the dearest route to a GLP-1
  • The states it can prescribe in are not published

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard